Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$4.82 - $18.01 $187,016 - $698,788
-38,800 Reduced 89.61%
4,500 $25,000
Q1 2024

May 09, 2024

BUY
$8.47 - $18.93 $146,531 - $327,489
17,300 Added 66.54%
43,300 $515,000
Q4 2023

Feb 13, 2024

BUY
$5.55 - $19.62 $144,300 - $510,120
26,000 New
26,000 $486,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $66.1M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Belvedere Trading LLC Portfolio

Follow Belvedere Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belvedere Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belvedere Trading LLC with notifications on news.